Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1950 2
1952 2
1953 3
1954 9
1955 19
1956 29
1957 36
1958 37
1959 42
1960 38
1961 43
1962 72
1963 158
1964 161
1965 101
1966 112
1967 171
1968 160
1969 144
1970 164
1971 137
1972 112
1973 118
1974 138
1975 120
1976 110
1977 99
1978 84
1979 79
1980 96
1981 83
1982 101
1983 75
1984 79
1985 84
1986 72
1987 59
1988 43
1989 71
1990 63
1991 48
1992 69
1993 69
1994 59
1995 61
1996 63
1997 43
1998 59
1999 66
2000 68
2001 77
2002 89
2003 99
2004 70
2005 99
2006 80
2007 85
2008 96
2009 128
2010 111
2011 144
2012 113
2013 164
2014 168
2015 158
2016 179
2017 182
2018 216
2019 188
2020 177
2021 216
2022 224
2023 215
2024 78

Text availability

Article attribute

Article type

Publication date

Search Results

6,901 results

Results by year

Filters applied: . Clear all
Page 1
MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia.
Treon SP, Xu L, Yang G, Zhou Y, Liu X, Cao Y, Sheehy P, Manning RJ, Patterson CJ, Tripsas C, Arcaini L, Pinkus GS, Rodig SJ, Sohani AR, Harris NL, Laramie JM, Skifter DA, Lincoln SE, Hunter ZR. Treon SP, et al. N Engl J Med. 2012 Aug 30;367(9):826-33. doi: 10.1056/NEJMoa1200710. N Engl J Med. 2012. PMID: 22931316 Free article.
BACKGROUND: Waldenstrom's macroglobulinemia is an incurable, IgM-secreting lymphoplasmacytic lymphoma (LPL). ...CONCLUSIONS: MYD88 L265P is a commonly recurring mutation in patients with Waldenstrom's macroglobulinemia that can be useful …
BACKGROUND: Waldenstrom's macroglobulinemia is an incurable, IgM-secreting lymphoplasmacytic lymphoma (LPL). ...CONCLUS …
The epidemiology of Waldenstrom macroglobulinemia.
McMaster ML. McMaster ML. Semin Hematol. 2023 Mar;60(2):65-72. doi: 10.1053/j.seminhematol.2023.03.008. Epub 2023 Mar 31. Semin Hematol. 2023. PMID: 37099032 Free PMC article. Review.
Waldenstrom macroglobulinemia (WM) is a rare subtype of non-Hodgkin lymphoma characterized by the presence of lymphoplasmacytic lymphoma (LPL) in the bone marrow accompanied by a monoclonal immunoglobulin type M (IgM) in the serum. ...Since the inaugural meeting of …
Waldenstrom macroglobulinemia (WM) is a rare subtype of non-Hodgkin lymphoma characterized by the presence of lymphoplasmacyti …
[Waldenstrom's macroglobulinemia].
Watanabe R. Watanabe R. Rinsho Ketsueki. 2015 Oct;56(10):2074-85. doi: 10.11406/rinketsu.56.2074. Rinsho Ketsueki. 2015. PMID: 26458447 Japanese.
Waldenstrom macroglobulinemia (WM) is a rare and incurable B-cell neoplasm characterized by lymphoplasmacytic bone marrow infiltration and the production of serum monoclonal immunoglobulin M. ...
Waldenstrom macroglobulinemia (WM) is a rare and incurable B-cell neoplasm characterized by lymphoplasmacytic bone marrow infi …
Genomic Landscape of Waldenstrom Macroglobulinemia.
Treon SP, Xu L, Liu X, Hunter ZR, Yang G, Castillo JJ. Treon SP, et al. Hematol Oncol Clin North Am. 2018 Oct;32(5):745-752. doi: 10.1016/j.hoc.2018.05.003. Epub 2018 Jul 25. Hematol Oncol Clin North Am. 2018. PMID: 30190014 Review.
Next-generation sequencing has revealed recurring somatic mutations in Waldenstrom macroglobulinemia (WM). Common mutations include MYD88 (95%-97%), as well as CXCR4 (30%-40%), ARID1A (17%), and CD79B (8%-15%), which are typically found in MYD88-mutated patients. .. …
Next-generation sequencing has revealed recurring somatic mutations in Waldenstrom macroglobulinemia (WM). Common mutations in …
Managing complications secondary to Waldenstrom's macroglobulinemia.
Pessach I, Dimopoulos MA, Kastritis E. Pessach I, et al. Expert Rev Hematol. 2021 Jul;14(7):621-632. doi: 10.1080/17474086.2021.1947236. Epub 2021 Jul 2. Expert Rev Hematol. 2021. PMID: 34170207 Review.
Introduction: Waldenstrom's macroglobulinemia (WM) is a rare lymphoma characterized by the accumulation of IgM-secreting lymphoplasmacytic cells in the bone marrow and other organs. ...
Introduction: Waldenstrom's macroglobulinemia (WM) is a rare lymphoma characterized by the accumulation of IgM-secretin …
Waldenstrom Macroglobulinemia: Genomic Aberrations and Treatment.
Kapoor P, Ansell SM, Braggio E. Kapoor P, et al. Cancer Treat Res. 2016;169:321-361. doi: 10.1007/978-3-319-40320-5_16. Cancer Treat Res. 2016. PMID: 27696269 Review.
Waldenstrom macroglobulinemia (WM) is a rare, indolent, and monoclonal immunoglobulin M-associated lymphoplasmacytic disorder with unique clinicopathologic characteristics. ...
Waldenstrom macroglobulinemia (WM) is a rare, indolent, and monoclonal immunoglobulin M-associated lymphoplasmacytic disorder …
How to manage waldenstrom's macroglobulinemia in 2024.
Grunenberg A, Buske C. Grunenberg A, et al. Cancer Treat Rev. 2024 Apr;125:102715. doi: 10.1016/j.ctrv.2024.102715. Epub 2024 Mar 5. Cancer Treat Rev. 2024. PMID: 38471356 Review.
Clinical management of Waldenstrom's Macroglobulinemia has seen major progress in the recent years, triggered by our improved understanding of the biology of the disease and the development of new therapies. ...
Clinical management of Waldenstrom's Macroglobulinemia has seen major progress in the recent years, triggered by our im …
Report of consensus panel 1 from the 11(th) International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naive patients.
Buske C, Castillo JJ, Abeykoon JP, Advani R, Arulogun SO, Branagan AR, Cao X, D'Sa S, Hou J, Kapoor P, Kastritis E, Kersten MJ, LeBlond V, Leiba M, Matous JV, Paludo J, Qiu L, Tam CS, Tedeschi A, Thomas SK, Tohidi-Esfahani I, Varettoni M, Vos JM, Garcia-Sanz R, San-Miguel J, Dimopoulos MA, Treon SP, Trotman J. Buske C, et al. Semin Hematol. 2023 Mar;60(2):73-79. doi: 10.1053/j.seminhematol.2023.03.005. Epub 2023 Mar 29. Semin Hematol. 2023. PMID: 37099027 Clinical Trial.
Consensus Panel 1 (CP1) of the 11(th) International Workshop on Waldenstrom's Macroglobulinemia (IWWM-11) was tasked with updating guidelines for the management of symptomatic, treatment-naive patients with WM. ...
Consensus Panel 1 (CP1) of the 11(th) International Workshop on Waldenstrom's Macroglobulinemia (IWWM-11) was tasked wi …
Waldenstrom's macroglobulinemia.
Dimopoulos MA, Galani E, Matsouka C. Dimopoulos MA, et al. Hematol Oncol Clin North Am. 1999 Dec;13(6):1351-66. doi: 10.1016/s0889-8588(05)70130-1. Hematol Oncol Clin North Am. 1999. PMID: 10626154 Review.
Waldenstrom's macroglobulinemia is an unusual low-grade lymphoplasmacytic lymphoma characterized by the production of monoclonal IgM. ...
Waldenstrom's macroglobulinemia is an unusual low-grade lymphoplasmacytic lymphoma characterized by the production of m …
Waldenstrom's macroglobulinemia.
McKenna JA. McKenna JA. Clin J Oncol Nurs. 2002 Sep-Oct;6(5):283-6. doi: 10.1188/02.CJON.283-286. Clin J Oncol Nurs. 2002. PMID: 12240489 Review.
Waldenstrom's macroglobulinemia (WM) is a rare monoclonal gammopathy. ...
Waldenstrom's macroglobulinemia (WM) is a rare monoclonal gammopathy. ...
6,901 results